False hope
There have been some studies suggesting that GLP-1 medications reduce symptoms of schizophrenia in animals
Trademark Notice: Wegovy is a registered trademark of Novo Nordisk A/S
Key Takeaways GLP-1 medications started as diabetes drugs but are now approved for weight loss due to their effects on appetite and satiety
As experts continue to study the impact that GLP-1s have on health outcomes, state budgets, peoples lives and out-of-pocket costs, it is expected that the drugs will remain a topic of conversation among state lawmakers, Medicaid agencies, stakeholder groups and many others during the coming 2025 legislative session
Despite the limitations of real-world observational studiesincluding the absence of randomization, control for confounding variables, and inability to establish causalityresearches offer confidence regarding the pancreatic safety profiles of GLP-1 RAs [55,61]